Royal Bank of Canada
ZBIO

Royal Bank of Canada’s Zenas BioPharma ZBIO Stock Holding History

Royal Bank of Canada’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-544
Closed -$20K – 7828
2025
Q4 		$20K Sell
544
-11,337
-95% -$373K ﹤0.01% 6059
2025
Q3 		$265K Buy
11,881
+10,547
+791% +$172K ﹤0.01% 4906
2025
Q2 		$13K Buy
1,334
+880
+194% +$8.57K ﹤0.01% 6420
2025
Q1 		$4K Sell
454
-686
-60% -$5.37K ﹤0.01% 6449
2024
Q4 		$9K Buy
+1,140
New +$17.8K ﹤0.01% 6389

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Royal Bank of Canada's ZBIO Position: Q1 2026 in Review

Royal Bank of Canada sold out of Zenas BioPharma (ZBIO) in Q1 2026, closing a stake of 544 shares — an estimated $20K sold.

Royal Bank of Canada first reported a position in ZBIO in Q4 2024 and held it in 5 quarters. The position peaked at $265K in Q3 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Royal Bank of Canada reported no remaining Zenas BioPharma position as of Q1 2026 after selling out during the quarter.
  • Royal Bank of Canada sold 544 Zenas BioPharma shares in Q1 2026, an estimated $20K.
  • Royal Bank of Canada first reported a position in Zenas BioPharma in Q4 2024 and held it in 5 quarters.
  • Royal Bank of Canada's Zenas BioPharma position peaked at $265K in Q3 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.